This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

This study has been completed.
Information provided by:
University Children’s Hospital Tuebingen Identifier:
First received: December 28, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted
Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.

Systemic Aspergillosis Systemic Candidiasis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Safety, Feasibility and Efficacy of Caspofungin Versus Liposomal Amphotericin B as Antifungal Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients - a Retrospective Phase I/II Study

Resource links provided by NLM:

Further study details as provided by University Children’s Hospital Tuebingen:

Study Start Date: August 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Pediatric patients undergoing allogeneic stem cell transplantation

Inclusion Criteria:

  • Pediatric patients under the age of 18 years
  • Pediatric patients after HSCT treated with caspofungin
  • Pediatric patients after HSCT treated with liposomal amphotericin

Exclusion Criteria:

  • Pediatric patients with uncontrolled hematological malignancies
  • Pediatric patients with IFI at start of HSCT
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01040156

University Children's Hospital
Tuebingen, Germany, 72076
Sponsors and Collaborators
University Children’s Hospital Tuebingen
Principal Investigator: Ingo Mueller, M.D. UCHT
  More Information Identifier: NCT01040156     History of Changes
Other Study ID Numbers: UCHT-1209
Study First Received: December 28, 2009
Last Updated: December 28, 2009

Additional relevant MeSH terms:
Skin Diseases, Infectious
Skin Diseases
Liposomal amphotericin B
Antifungal Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents processed this record on June 23, 2017